- Home
- AUPH
as 07-26-2024 4:00pm EST
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Aurinia Pharmaceuticals Inc AUPH prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 796.6M | IPO Year: | 1999 |
| Target Price: | $10.33 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.71 - $12.43 | Next Earning Date: | 08-01-2024 |
| Revenue: | $191,407,000 | Revenue Growth: | 30.37% |
| Revenue Growth (this year): | 32.67% | Revenue Growth (next year): | 23.66% |
Stock Insider Trading Activity of Aurinia Pharmaceuticals Inc (AUPH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leversage Jill | AUPH | Director | May 21 '24 | Sell | $5.74 | 5,610 | $32,201.40 | 12,918 | SEC Form 4 |
| Balakrishnan Brinda | AUPH | Director | May 21 '24 | Sell | $5.74 | 520 | $2,984.80 | 17,523 | SEC Form 4 |
| MacKay-Dunn R. Hector | AUPH | Director | May 21 '24 | Sell | $5.74 | 5,630 | $32,316.20 | 18,595 | SEC Form 4 |
| Billen Daniel | AUPH | Director | May 21 '24 | Sell | $5.74 | 5,252 | $30,146.48 | 28,141 | SEC Form 4 |
| Jayne David R.W. | AUPH | Director | May 21 '24 | Sell | $5.74 | 4,946 | $28,390.04 | 44,364 | SEC Form 4 |
| Habig Scott Michael | AUPH | Chief Commercial Officer | Mar 6 '24 | Sell | $5.60 | 17,777 | $99,551.20 | 474,587 | SEC Form 4 |
| Donley Matthew Maxwell | AUPH | EVP, Ops & Strategy | Mar 6 '24 | Sell | $5.51 | 40,665 | $224,064.15 | 584,072 | SEC Form 4 |
| Robertson Stephen P. | AUPH | EVP, General Counsel | Mar 6 '24 | Sell | $5.60 | 57,745 | $323,372.00 | 443,824 | SEC Form 4 |
| Greenleaf Peter | AUPH | Chief Executive Officer | Mar 6 '24 | Sell | $5.60 | 126,981 | $711,093.60 | 1,522,114 | SEC Form 4 |
| Knappertz Volker | AUPH | EVP, Research and Development | Feb 27 '24 | Sell | $6.10 | 4,930 | $30,073.00 | 319,128 | SEC Form 4 |
| Knappertz Volker | AUPH | EVP, Research and Development | Feb 20 '24 | Sell | $5.48 | 25,146 | $137,800.08 | 324,058 | SEC Form 4 |
| Habig Scott Michael | AUPH | Chief Commercial Officer | Feb 20 '24 | Sell | $5.48 | 15,867 | $86,951.16 | 492,364 | SEC Form 4 |
| Miller Joseph M | AUPH | Chief Financial Officer | Mar 2 '23 | Sell | $8.78 | 11,398 | $100,074.44 | 331,112 | SEC Form 4 |
| Greenleaf Peter | AUPH | Chief Executive Officer | Mar 2 '23 | Sell | $8.78 | 33,047 | $290,152.66 | 982,671 | SEC Form 4 |
| Robertson Stephen P. | AUPH | EVP, General Counsel | Mar 2 '23 | Sell | $8.78 | 19,644 | $172,474.32 | 303,122 | SEC Form 4 |
Latest Aurinia Pharmaceuticals Inc News
AUPH Breaking Stock News: Dive into AUPH Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Zacks
15 days ago
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Business Wire
25 days ago
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Simply Wall St.
a month ago
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%
Zacks
a month ago
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Business Wire
a month ago
Aurinia Announces 2024 Annual General Meeting Results
Simply Wall St.
2 months ago
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now
Business Wire
2 months ago
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Compare AUPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.